Search research articles

Related Concept Videos

Structure-Activity Relationships and Drug Design

Structure-Activity Relationships and Drug Design

Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Engineering Biosensors to Enhance Monoterpene Indole Alkaloid Production in Yeast.

bioRxiv : the preprint server for biology·2026

Same author

Ligify 2.0: a web server for predicted small molecule biosensors.

Nucleic acids research·2026

Same author

Rational design of selective bispecific EPO-R/CD131 agonists.

Protein engineering, design & selection : PEDS·2025

Same author

groovDB in 2026: a community-editable database of small molecule biosensors.

Nucleic acids research·2025

Same author

A coronaviral pore-replicase complex links RNA synthesis and export from double-membrane vesicles.

Science advances·2024

Same author

Ten Years of the Synthetic Biology Summer Course at Cold Spring Harbor Laboratory.

ACS synthetic biology·2024

Same journal

Layered social competition coordinates reproductive hierarchy formation in ants.

bioRxiv : the preprint server for biology·2026

Same journal

Combination epigenetic-targeted therapy increases the immunogenicity of poorly immunogenic sarcomas.

bioRxiv : the preprint server for biology·2026

Same journal

Loss of LanC-like proteins delays post-injury regeneration of aging skeletal muscles.

bioRxiv : the preprint server for biology·2026

Same journal

Integrative Transfer Network: Deep Transfer Learning Across Populations and Prediction Targets.

bioRxiv : the preprint server for biology·2026

Same journal

Confidence-supported label-free metabolic imaging with FPhaS phase autofluorescence microscopy.

bioRxiv : the preprint server for biology·2026

Same journal

Sequence-encoded autoinhibition couples mRNA decapping activity to phase separation.

bioRxiv : the preprint server for biology·2026

See all related articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Search research articles

Related Experiment Video

Updated: Apr 29, 2026

A GPC3-targeting Bispecific Antibody, GPC3-S-Fab, with Potent Cytotoxicity

A GPC3-targeting Bispecific Antibody, GPC3-S-Fab, with Potent Cytotoxicity

Published on: July 12, 2018

Rational design of selective bispecific EPO-R/CD131 agonists.

Kailyn E Doiron^1,2,3, Jeffrey C Way^1,2, Pamela A Silver^1,2

¹Department of Systems Biology, Harvard Medical School, Boston, Massachusetts, 02115, USA.

Biorxiv : the Preprint Server for Biology

|September 5, 2025

Summary

This summary is machine-generated.

This study models the erythropoietin receptor (EPO-R)/CD131 complex and develops bispecific proteins to selectively activate it. These engineered proteins successfully activate EPO-R/CD131 signaling, offering new therapeutic avenues.

More Related Videos

Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody

Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody

Published on: May 16, 2020

Tracking Bispecific Antibody-Induced T Cell Trafficking Using Luciferase-Transduced Human T Cells

Tracking Bispecific Antibody-Induced T Cell Trafficking Using Luciferase-Transduced Human T Cells

Published on: May 12, 2023

Related Experiment Videos

Last Updated: Apr 29, 2026

A GPC3-targeting Bispecific Antibody, GPC3-S-Fab, with Potent Cytotoxicity

A GPC3-targeting Bispecific Antibody, GPC3-S-Fab, with Potent Cytotoxicity

Published on: July 12, 2018

Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody

Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody

Published on: May 16, 2020

Tracking Bispecific Antibody-Induced T Cell Trafficking Using Luciferase-Transduced Human T Cells

Tracking Bispecific Antibody-Induced T Cell Trafficking Using Luciferase-Transduced Human T Cells

Published on: May 12, 2023

Area of Science:

Molecular Biology
Structural Biology
Immunology

Background:

Erythropoietin (EPO) signals through EPO receptor (EPO-R) homodimers (EPO-R/EPO-R) on hematopoietic cells.
EPO signaling via EPO-R/CD131 heterodimers on non-hematopoietic cells is poorly understood and structurally uncharacterized.
Activating EPO-R/CD131 offers potential for novel therapeutic strategies beyond traditional EPO applications.

Purpose of the Study:

To elucidate the structural basis of EPO-R/CD131 complex formation.
To design and validate bispecific proteins that selectively activate EPO-R/CD131 signaling.
To investigate the potential of bispecific scaffolds for cytokine receptor modulation.

Main Methods:

Construction of a structural model for the EPO-R/CD131 complex.
Design and synthesis of anti-EPO-R and anti-CD131 bispecific proteins in various formats (tandem scFv, bispecific antibody).
Assessment of STAT5 phosphorylation as a readout for EPO-R/CD131 activation in response to engineered proteins.

Main Results:

A structural model of the EPO-R/CD131 complex was successfully generated.
Engineered bispecific proteins, particularly tandem scFv and bispecific antibody formats, selectively activated EPO-R/CD131 signaling.
Activation was confirmed by STAT5 phosphorylation, distinct from EPO-R/EPO-R engagement.
Modifications in binding domain arrangement and linker length influenced activation, aligning with the structural model.

Conclusions:

Bispecific protein engineering provides a viable strategy for selective cytokine receptor activation.
The developed bispecific proteins demonstrate potent EPO-R/CD131 agonism.
This work lays the groundwork for further investigation into EPO-R/CD131 biology and its therapeutic potential.